New hope for high-risk prostate cancer: drug duo after surgery may stop recurrence
NCT ID NCT07282197
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether adding darolutamide (a pill that blocks male hormones) to standard hormone therapy after prostate removal can keep cancer from coming back in high-risk patients. About 40 men will take the combination for 12 months and be followed for 2 years. The main goal is to see how many remain free of biochemical recurrence (a rise in PSA levels).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Darolutamide (a drug that blocks androgen receptors) plus androgen-deprivation therapy (ADT, hormone therapy that lowers testosterone)
What this could lead to
If successful, this could offer a new way to delay prostate cancer recurrence after surgery, potentially reducing the need for more aggressive treatments.
What could go wrong
This is a small, early-phase trial with only 40 participants and no comparison group, so results may not apply broadly. Side effects from darolutamide and hormone therapy can include fatigue, hot flashes, and cardiovascular risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••